Key Points
- BDX EVP Michael David Garrison sold 1,100 shares on June 10 at an average price of $151.48, totaling about $166,628. After the sale, he still directly owned 14,272 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
- The company recently posted stronger-than-expected quarterly results, reporting EPS of $2.90 versus the $2.77 estimate and revenue of $4.71 billion versus $4.67 billion expected. Revenue rose 5.2% year over year, and Becton, Dickinson raised its FY2026 EPS guidance to $12.52-$12.72.
- BDX continues to pay a quarterly dividend of $1.05 per share, or $4.20 annualized, for a yield of about 2.8%. However, the dividend payout ratio is high at 106.33%, while Wall Street’s consensus rating remains “Hold” with an average target price of $183.64.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president directly owned 14,272 shares of the company's stock, valued at approximately $2,161,922.56. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Becton, Dickinson and Company Trading Down 0.3%
Shares of Becton, Dickinson and Company stock opened at $147.40 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a market cap of $40.62 billion, a PE ratio of 37.32, a P/E/G ratio of 10.46 and a beta of 0.22. The stock has a fifty day moving average price of $150.21 and a 200-day moving average price of $174.25. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the firm posted $3.35 EPS. The business's revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 106.33%.
Wall Street Analysts Forecast Growth
BDX has been the topic of a number of research reports. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Argus lowered their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a report on Monday, March 23rd. Piper Sandler lowered their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Finally, Evercore lifted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $183.64.
View Our Latest Stock Report on Becton, Dickinson and Company
Institutional Investors Weigh In On Becton, Dickinson and Company
Several institutional investors have recently added to or reduced their stakes in BDX. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at about $25,000. Steph & Co. lifted its holdings in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Meeder Asset Management Inc. lifted its holdings in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Finally, Main Street Group LTD purchased a new stake in Becton, Dickinson and Company during the first quarter valued at about $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
